Dr. Smith’s research interests include: 1) growth factor-dependent mitogenesis in tumor development, specifically MAPK (ERK1/2) signaling and regulation in primary (non-transformed normal) epithelial and ES cells and the disregulation of the kinase in ovarian and breast epithelial-derived cancers; 2) Disabled-2 function in tumor suppression. Dab2, an adaptor protein involved in clathrin-coated vesicle endocytosis and sorting, was first identified as a mitogen-stimulated phosphoprotein differentially lost in ovarian cancer. Dr. Smith’s goal is to understand the function of Dab2 related to ovarian tumor development and in epithelial-like differentiation; 3) Cyclooxygenase involvement in reducing the risk of ovarian cancer. Dr. Smith’s work has used a menopause-like mouse model to investigate the utility and mechanism of COX inhibition in reducing the risk of ovarian carcinoma.
Selected Cancer-Related Publications
Smith ER, Zhang XY, Capo-Chichi CD, Chen X, Xu XX. Increased expression of Syne1/nesprin-1 facilitates nuclear envelope structure changes in embryonic stem cell differentiation. Dev Dyn 240:2245-55, 2011. Read more »
Smith ER, Xu XX. REDD1, a new Ras oncogenic effector. Cell Cycle 8:675-6, 2009. Read more »
Yang DH, Smith ER, Cai KQ, Xu XX. c-fos elimination compensates for disabled-2 requirement in mouse extraembryonic endoderm development. Dev Dyn 238:514-523, 2009. Read more »